ChatGPT

Restated Rules

Budget Discipline: We cannot use any new capital beyond the current portfolio value. We must carefully track cash usage for each trade, ensuring we *only* deploy the available cash on hand. No leverage or margin is allowed – only the cash shown in the portfolio can be invested.

Execution Limits: We will trade **full shares only**. We are not permitted to trade options, sell short, use margin, or engage in any derivative or leveraged instruments. All positions are **long-only** equity positions. Any orders should preferably be limit orders (for better execution control), or market orders only if justified. No partial-share trades are allowed.

Universe Constraints: We are restricted to **U.S. micro-cap stocks under $300M market cap**. Before adding any stock, we **must confirm its market capitalization is below $300M** based on the latest closing price. If any stock we currently hold has grown above $300M, we can continue to hold or sell it, but we cannot add to that position. We also need to consider liquidity – micro-caps often have low average volume and larger bid/ask spreads, so we must size our orders modestly relative to volume to avoid slippage.

Risk Control: We must adhere to provided **stop-loss levels** and position sizing guidelines. Any time a stop-loss level is breached (intraday or at close), it should be flagged and likely trigger an action (e.g. sell) to contain losses. We need to immediately address any stop breaches. Overall portfolio risk (position concentrations, correlation) should be managed – no single position should dominate the portfolio beyond what our plan allows, and high-risk positions should be counterbalanced by either smaller size or other safer positions.

Cadence: We are in the **weekly deep research window** (every Sunday). This is the opportunity to thoroughly reassess the portfolio, incorporate new information, and decide on **any portfolio changes (add, trim, exit, new buys)**. We have full discretion to act in the portfolio's best interest to improve risk-adjusted returns. Any trades we plan will presumably be executed when the market next opens (Monday) under the specified order parameters.

Complete Freedom: Within these constraints, we have **complete decision-making freedom**. The objective is to **optimize risk-adjusted return** for the remainder of the experiment. That means we can be bold in pursuing high-alpha opportunities (as we have done with catalyst-driven microcaps) but must always weigh the risks and respect the rules above. Generating alpha is key, but preserving capital under downside scenarios is equally important.

Deep Research Requirements: Our task this week is to **reevaluate all current holdings** in light of any new developments and consider **new candidates** that might strengthen the portfolio. For each holding, we need to articulate whether to keep holding, add more, trim down, or exit entirely – backed by a clear rationale (fundamental updates, technical signals, risk changes, etc). For any new stock considered, we should perform due diligence: confirm it meets the criteria (micro-cap, U.S., catalyst or value case, etc), assess its catalyst/timeline, and ensure adding it won't break our risk limits or liquidity constraints. Every decision (hold or trade) must be justified by our research findings.

Order Execution Policy: We assume standard U.S. equity market execution. Unless specified otherwise, a "limit DAY" order means it will try to execute at our limit price or better during the next trading session (and will expire end-of-day if not filled). A "GTC" (Good-Till-Cancelled) limit order remains active beyond one day until filled or manually canceled (or up to 60-90 days on some broker platforms). We should clarify if our orders are DAY or GTC. Typically, we prefer limit orders at a sensible price near the last close for control. If we use a market order, we must justify why (e.g. extremely liquid stock and urgency). All *stop-losses* we mention will be presumably entered as stop orders (or mental stops to monitor) that trigger a market sell if the price falls to that level – we will specify those stops and the reasoning for their placement (technical support, risk tolerance, etc).

Summary: In short, we must manage the portfolio within a strict budget, trade only micro-cap U.S. stocks (full shares, long positions), keep an eye on liquidity and stops, and we can adjust anything this week as needed. The goal is to maximize upside (alpha) from our high-conviction ideas while strictly limiting downside via stops and prudent sizing. All decisions will be evidence-based from deep research.

Research Scope

For this deep-dive, we conducted **extensive research on each current holding and potential new candidates**. Our analysis included:

- **Reviewing Company News & Filings:** We checked recent press releases, SEC filings, and credible news articles for **Milestone Pharmaceuticals (MIST)**, **Aytu BioPharma (AYTU)**, and **Microbot Medical (MBOT)**. We focused on any **material updates in the past week**: trial progress, FDA updates, product launch news, financing or partnerships, etc. This included confirming known catalyst dates (like MIST's FDA decision) and any interim developments. For example, we confirmed MIST's PDUFA date (Dec 13, 2025) and that prior FDA issues were CMC-related (impurities, inspections) with **no concerns on efficacy** [1] [2]. We also noted AYTU's recent patent exclusivity extension for its drug EXXUA and its ongoing launch preparations [3] [4]. For MBOT, we reviewed recent announcements about its product launch timeline (limited release in Q4 2025, full launch in April 2026) [5] [6] and any trading alerts (since it hit our stop level).

- **Market Data & Technicals:** We gathered the latest stock prices, volume, and market cap information for each holding (as of Oct 31, 2025, since that's the last trading day). For instance, MIST closed around $1.92 [7] (market cap ~$160M), AYTU around $2.27 [8] (market cap ~$22.5M [9]), and MBOT around $2.23 (market cap ~$149M) after a volatile week. We also looked at their recent trading ranges and whether any had breached key technical levels (notably, MBOT trading below its $2.30 stop).

- **Catalyst Verification:** We double-checked timelines for each stock's major catalyst:

- MIST: NDA resubmission accepted; **FDA decision (PDUFA)** on Dec 13, 2025 [1]. No new delays reported.
- AYTU: **Commercial launch of EXXUA** (antidepressant) in Q4 2025 is on track [3] [4]. No negative updates on timing; the company participated in investor conferences to build awareness.

- MBOT: **LIBERTY robotic system limited market release** expected in Q4 2025 (as planned) with broader launch April 2026 [5] [6]. We verified the company secured a logistics partner and is proceeding with commercialization steps.

- Additionally, we scanned for any competitor or sector news that might affect these (e.g., other FDA approvals in arrhythmia or depression that could change sentiment).

- **New Ideas Screening:** We explored **potential new micro-cap candidates** by scanning FDA calendars, biotech news, and micro-cap forums for upcoming catalysts in Q4 2025. We identified a few promising ones:

- A **semiconductor micro-cap (Peraso, PRSO)** in an active **strategic review/M&A situation**, where an external bidder has made an offer [10] and negotiations are ongoing [11].
- A **psychedelic biotech (Compass Pathways, CMPS)** which recently achieved a positive Phase 3 result in treatment-resistant depression (a novel psilocybin therapy) [12] – giving it a first-mover advantage in a new mental health treatment approach – and might attract partnership or buyout interest.
- A **micro-cap oil & gas producer (Evolution Petroleum, EPM)** as a more stable, dividend-paying candidate [13] [14] to diversify risk, given its steady cash flows and 46-quarter streak of dividends.

- (We discuss these in **Candidate Set** below.)

- **Risk & Liquidity Analysis:** For each current and potential holding, we evaluated trading liquidity (average volume vs. our position size) and any *red flags* (compliance issues, going-concern warnings, etc). For example, we noted **Azitra (AZTR)** as a possible biotech candidate, but it's extremely small (market cap ~$3M) and received a NYSE non-compliance notice [15], signaling high financial risk – we decided to pass on that due to excessive risk despite a potential catalyst. We ensured all our picks stay under $300M cap and have enough daily volume that our trades (only a few shares) won't move the price.

- **Stop-Loss and Technical Check:** We specifically checked if any current holding hit its stop:

- **MBOT alert:** MBOT traded as low as ~$2.13 intraday this week and **closed at $2.16–2.23 on Oct 30-31**, which is **below our $2.30 stop**. This **stop-loss breach** is noted and addressed in our actions.
- MIST and AYTU did *not* hit their stops ($1.70 and $1.80 respectively); they remained safely above those levels.
- We considered whether to adjust any stop levels (e.g., tighten or loosen given volatility and time remaining) – we'll detail that in the actions section.

In summary, our research covered **fundamental developments, catalyst timelines, market data, and risk factors** for all holdings, plus identification of new opportunities. We have all the necessary information to proceed with an informed action plan, complete with sources to back our thesis and numbers.

Current Portfolio Assessment

Let's summarize the current portfolio holdings as we start Week 19, including each stock's role in our strategy, entry point, cost basis, stop-loss, conviction level, and current status:

Ticker (Company)	Role & Thesis	Entry Date	Avg. Cost Basis	Current Price (Oct 31)	Stop-Loss	Conviction & Status
MIST (Milestone Pharmaceuticals) – Biotech FDA Catalyst	*"Home-run" FDA approval play.* Lead drug *etripamil (nasal spray)* for PSVT; PDUFA Dec 13, 2025 is a binary catalyst. Resubmitted after addressing manufacturing issues; no efficacy concerns [1].	~Jul 10, 2025 (FDA resubmission accepted)	~$1.85/ share	~$1.92 [7]	$1.70 (GTC)	**High Conviction – HOLD.** Thesis intact (potential first-in-class PSVT rescue therapy). Price stable in high-$1.8s. No news = "waiting mode" for FDA. Will hold through catalyst with stop to contain downside.
AYTU (Aytu BioPharma) – Small Pharma Commercial Launch	*"Cusp of launch" new product play.* Just launched **EXXUA™**, a novel antidepressant (5-HT1A agonist) with **no sexual side effects** vs SSRIs [16]. Targeting huge $22B depression market [17].	~Jul 24, 2025 (post-EXXUA deal financing)	~$2.00/ share	~$2.27 [8]	$1.80 (GTC)	**High Conviction – HOLD.** EXXUA launch on track for Q4 [3]. Valuation is low (~$22M market cap [18]) relative to opportunity. No negative updates; maintaining position into launch. Stop at $1.80 for risk management.

Ticker (Company)	Role & Thesis	Entry Date	Avg. Cost Basis	Current Price (Oct 31)	Stop-Loss	Conviction & Status
MBOT (Microbot Medical) – Medtech FDA-cleared Device Launch	*"First-of-its-kind" robotic surgery device.* Received FDA 510(k) clearance in Aug for **LIBERTY**, a single-use endovascular robot. Limited market release Q4 2025, full launch planned April 2026 [5]. Recent ~$29M cash infusion via warrant exercises strengthens balance sheet (supports commercialization).	~Aug 21, 2025 (post-clearance pullback)	~$2.50/ share (est.)	~$2.23 (Oct 31 close)	$2.30 (stop)	**Medium Conviction – *BREACH*.** *Status:* **Stop-Loss Triggered** – The stock drifted below $2.30 support (closed ~$2.23). We planned a tight stop due to volatility; it hit. **Action needed:** Reevaluate vs thesis. (Thesis positive, but risk of further slide). Decision: likely **Exit to protect capital** (see actions).
Cash Balance	N/A	N/A	(Cash on hand before trades)	$18.50	N/A	We had kept minimal cash (only ~$2 last week) but now have ~$18.50, reflecting previous small additions and any sales. This cash is available for new opportunities or buffer.

Key Points from Assessment:

- **MIST:** Remains the potential big winner (or loser) depending on Dec 13 FDA decision. Our cost is around mid-$1s; it's hovering just below $2. We are comfortable holding given no change in the catalyst timeline or company fundamentals. Conviction remains **very high** (it's our largest position). We have a stop at $1.70 (~11% below current) to guard against a pre-decision downturn or worst-case FDA rejection (which could send it < $1). Upside if approved could be several-fold (Wells Fargo's coverage initiation gave a $4.00 target [19], citing transformative potential).

- **AYTU:** A diversified "safer" play within our high-risk basket – it's a commercial-stage pharma launching a unique drug in a large market. The stock is flat to slightly up from our entry (~$2 to $2.27 now). No issues have arisen; in fact, management recently highlighted that EXXUA's patent exclusivity extends to 2030 [3] which boosts the long-term value. We keep our stop at $1.80 to limit downside (~20% risk) in case the launch disappoints or any negative surprise. Conviction remains **high** given the low valuation vs potential sales.

- **MBOT:** This was our smaller, speculative medtech bet. We knew it'd be volatile post-clearance. Unfortunately, *the stock broke below our stop $2.30* this week, hitting lows ~$2.13 before a mild bounce to ~$2.23. This means our risk control line was crossed. We must **flag this breach and take action**. The thesis (first robotic system of its kind, Q4 rollout) is still promising, and fundamentally nothing bad was announced – the decline likely due to normal post-news profit taking and possibly general small-cap weakness. However, discipline says we should not ignore a stop trigger. We need to decide whether to give MBOT more leash or exit. Given it closed *below* stop for two days, the prudent approach is to **exit MBOT to protect from deeper losses**, and possibly reallocate that capital to a new idea with better short-term momentum. Our conviction in MBOT's story is medium (we like it but it's longer timeline and high volatility). We'll realize a small loss but safeguard against a larger slide. (We note MBOT's next major inflection might not come until it reports initial market acceptance – which could be after our experiment ends.)

- **Cash:** We find ourselves with ~$18.50 cash (which is a higher balance than last week, likely due to minor portfolio value changes or previous trims). After any exits (like MBOT), cash will increase further. We intend to **put cash to work** if we find a compelling new catalyst stock – we don't want idle cash drag in this final stretch, unless needed as a buffer. But we'll keep a few dollars unallocated as a cushion for volatility or unforeseen fees.

Overall, the current portfolio is **highly concentrated in catalyst-driven microcaps** (MIST, AYTU, and until now MBOT). This affords big upside potential, but also non-trivial downside risk. Each position has independent drivers (regulatory approval, product launch, device commercialization), which is good for diversification of *catalyst type*. However, all are in healthcare/biotech broadly, meaning they are somewhat correlated with sentiment in that sector. We are comfortable with that given the stage of the experiment (we intentionally chose these high-risk, high-reward plays for the home stretch). With MBOT likely being removed, we will seek at least one new **independent catalyst** to maintain 3 active positions – ideally in a different industry or catalyst type to reduce correlation.

Candidate Set

Considering the portfolio adjustments, we scouted several **new micro-cap candidates** that meet our criteria (sub-$300M, near-term catalyst or mispricing, and sufficient liquidity). Here are a few standouts:

- **PRSO (Peraso Inc.) – M&A Speculation in Semiconductors:** Peraso is a ~$10M market cap fabless semiconductor company (mmWave wireless technology) that is currently **in play for a potential acquisition**. In mid-2025, **Mobix Labs made an unsolicited all-cash offer of $1.30/share** [10] (a 50%+ premium at the time) to acquire PRSO. The Peraso board didn't immediately accept, instead exploring alternatives. As of Oct 30, Peraso **signed a confidentiality agreement with Mobix to facilitate due diligence** [11], implying active negotiations. The stock has traded around $1.40 (as of Oct 31) in anticipation of a deal [20]. **Catalyst:** A definitive deal announcement could come at any time in the coming weeks. Upside could be another ~10-30% if a higher price is agreed (or even more if a bidding war emerges), whereas downside if talks collapse could send the stock back to ~$0.50–$0.80. **Liquidity:** Decent for a micro-cap (recent avg volume ~300–400k shares/day [20]). **Note:** This is an event-driven play uncorrelated to our biotech holdings. We'd need to manage risk via tight stop since it's binary on deal/no-deal outcome.

- **CMPS (Compass Pathways) – Pioneering Psychedelic Therapy:** Compass (~$250M cap at $6.30 [21]) is a biotech at the forefront of **psilocybin-based therapy for depression**. In late Oct 2025, they announced that their Phase 3 trial in treatment-resistant depression **met its primary endpoint with high statistical significance** [22]. This is a groundbreaking validation of psychedelic therapy. They have a second Phase 3 ongoing and are roughly a year from potential FDA approval. **Catalyst:** While FDA approval (and potential commercialization) is more of a 2026 event, near-term catalysts include potential **partnerships or buyout interest from big pharma** (given the positive data), as well as any breakthrough therapy designations or interim data from the second trial. The stock popped on the news, but investors remain cautious (the rally was modest, perhaps due to questions about implementation of psychedelic therapy). Trading ~60% below many analyst price targets [23], it offers asymmetric upside if sentiment improves. **Liquidity:** Good (~1.5M avg volume). **Note:** This adds exposure to an *entirely different domain (mental health/psychedelics)*, diversifying our catalysts. It's somewhat less binary than a one-day FDA decision, but still high-risk/high-reward. We'd treat it as a medium-term catalyst play.

- **EPM (Evolution Petroleum) – Steady Micro-Cap Value/Income:** EPM (~$200M cap) is an oil & gas production company that's *profitable and pays dividends*. It's included here as a **low-volatility counterbalance** to our biotech risk. EPM has **paid dividends for 46 consecutive quarters** [13] [14] (an impressive track record for a micro-cap) and avoids dilutive financing. It generates steady income from conventional oil/gas assets. **Catalyst:** There's no dramatic near-term event; rather, it's a value play that could grind higher if oil prices rise or if small-cap value stocks mean-revert. It also yields ~5% annually, which provides some return even if price stays flat (though our experiment ends in ~8 weeks, so we'd at most get one quarterly dividend of a few cents). **Liquidity:** Moderate (thinly traded). **Note:** While EPM won't double in a month barring an oil spike, it could **protect the portfolio's downside**. We'd consider it if we wanted to reduce overall risk – however, given our short timeline and desire for strong finish, we may favor more catalytic names. It's a candidate if we see stormy market conditions and want a safe harbor.

- *(Honorable Mention)* **PESI (Perma-Fix Environmental Services):** A $100M-cap environmental services firm with significant government cleanup contracts (e.g., Hanford nuclear site). It has potential earnings growth and is touted as a possible "10-bagger" over time by some analysts [24] [25]. We mention it for completeness, but its catalyst (ramping earnings from contracts) is more gradual and likely beyond our experiment timeframe. Liquidity is okay. We will keep an eye on it for longer-term interest but it's not an immediate catalyst play for year-end.

Each candidate above was vetted for market cap and liquidity (all under $300M and tradable). They represent a mix of **event-driven (PRSO)**, **sector innovation (CMPS)**, and **value/defensive (EPM)**. Our plan is to choose the one(s) that best complement our portfolio now.

Given our portfolio's current makeup (two healthcare high-risk plays), **adding a non-biotech catalyst (PRSO)** could improve diversification and exploit a potentially imminent event (a buyout). The **Compass (CMPS)** idea is also appealing for its longer-tail upside, but its catalyst may not fully play out by year-end (unless a surprise bid comes). **EPM** is safest but offers the least bang for the buck in the short run.

We will detail in the next section which candidate(s) we are actually going to initiate and why, as well as which current holding(s) we will exit or adjust.

Portfolio Actions

Based on the above analysis, here are the actions we will take for each holding and candidate:

1. Keep MIST – (No change, maintain full position): We are *holding* our entire **Milestone (MIST)** position. **Reason:** The core thesis is unchanged: we are now about 6 weeks from the FDA's decision on etripamil. This is the make-or-break moment we've been positioning for. The stock has been stable around ~$1.9, indicating neither anticipation nor panic yet – essentially in a wait-and-see equilibrium. We have **high conviction** that the risk/reward remains favorable: if approved, the stock could potentially gap up significantly (analysts' targets in the $3–4 range [19]), whereas a rejection, while painful, is mitigated by our stop. We're already sized appropriately and recently topped up last week with spare cash, so no additional buy is needed. We **keep our stop-loss at $1.70** to guard against any leak of negative news or a broader market sell-off. *Rationale:* MIST offers an independent catalyst that could generate portfolio-saving returns. We accept the binary risk but have controlled position size and stop to limit damage if it goes wrong. Thus, **Hold MIST** through the PDUFA decision.

2. Keep AYTU – (No change, maintain position): We will *continue to hold* **Aytu BioPharma (AYTU)** at our current size. **Reason:** AYTU's story – launching the first new-mechanism antidepressant in decades – is progressing as expected. The company **confirmed EXXUA's commercial launch in Q4 2025** (likely imminently) [3]. There's been no dilution since the summer financing, and they are actively marketing the story to investors. We still see a **multibagger potential** if EXXUA gains even modest traction given AYTU's tiny market cap (~$22M) [18]. Near-term, we anticipate possible press releases such as "Product now available" or early prescription figures, which could boost the stock. Downside risks (launch delays, low initial uptake) exist, but our stop at $1.80 provides a floor. Conviction remains **high**, so we'll neither trim nor add – just ride our current stake. *Rationale:* AYTU adds diversification in terms of catalyst (commercial execution vs. pure FDA binary) and could appreciate steadily on any good launch news. We're content with our exposure and will **Hold AYTU**, with the existing stop-loss intact.

3. Exit MBOT – (Sell entire position): We have decided to **exit Microbot Medical (MBOT)** completely. **Reason:** MBOT *breached our stop-loss* ($2.30) this week, which is a clear signal per our risk rules. We gave it a bit of leeway to see if it would quickly rebound (a slight rebound happened, to ~$2.23, but not above stop). However, it closed two consecutive days under $2.30, indicating technical weakness. Given MBOT's volatility, a breach could lead to further downside – for instance, it could retrace toward the $1.50 level (where many warrants were exercised) if selling pressure continues. While we still believe in the LIBERTY robot's promise (and nothing fundamentally negative occurred), the timeline for major validation/news (widespread hospital adoption, revenue) is longer-term (Q1/Q2 2026 for full rollout). Meanwhile, that capital could be redeployed into a catalyst that will play out *within our experiment*. We prefer to **protect our capital** and avoid the scenario of a slow bleed. By selling now, we lock in roughly a minor loss but free up ~$15–$18 in cash. *Rationale:* This is a disciplined risk management move. We always said we'd cut MBOT if it fell below $2.30 to avoid a large drawdown – we are sticking to that plan. We can reassess MBOT in the future once it finds a bottom or if new catalyst news emerges, but for this portfolio's purposes, **we are out**. (No partial trim; we'll exit the entire position in one go.)

4. Initiate PRSO – (New position, moderate size): We will **initiate a new long position in Peraso (PRSO)**, using a significant portion of the freed cash (from MBOT and existing cash). **Reason:** PRSO provides a *fresh catalyst (M&A)* that is decoupled from biotech risks, which improves our overall risk distribution. With Mobix's overtures and the confidentiality agreement in place, there is a realistic chance that a **buyout deal will be announced in the coming weeks** – potentially within our 8-week remaining window. The stock, at ~$1.43, trades slightly above the last known offer ($1.30) [10], implying the market expects either a higher bid or at least a decent probability of a deal. If a deal comes (say at $1.50–$1.80 or higher), we could see a quick ~10–30% gain. If negotiations fall apart, the downside is that PRSO could drop back to pre-offer levels (around $0.70). We will mitigate that risk by setting a **stop-loss (e.g. ~$1.10)** to limit loss to ~20-25%. Liquidity is adequate (hundreds of thousands shares trade most days), so our planned share count (a few dozen shares) is easily absorbed. *Rationale:* This move injects an event-driven play that diversifies our portfolio (tech sector, M&A catalyst). PRSO's risk/reward, *given we use a stop*, is favorable: essentially we risk a small portion of capital for a chance at a quick boost that is not correlated with FDA or launch outcomes of our other positions. We have **moderate conviction** that a deal will materialize (the presence of a serious bidder and ongoing talks is a positive sign). Even if it doesn't, the stop will prevent a catastrophic loss. Therefore, we will **Initiate a position in PRSO** with the intention to hold through the outcome of the strategic review process.

5. (Contingency) No action on CMPS or EPM now – (Watchlist only): We considered starting positions in **Compass Pathways (CMPS)** or **Evolution Petroleum (EPM)**, but after deliberation, we **will not add them at this time**. - For **CMPS**: while we like its story and it could be a big winner long-term, the next clear catalyst (besides general sentiment shifts) likely comes after our experiment (second Phase 3 data in 2026 or an NDA filing). It's also at ~$6+ already after the Phase 3 news, so the "run-up" might slow. We prefer to allocate our limited cash to PRSO which has a more defined near-term event. We'll keep CMPS on watch, in case it dips to an attractive level or if we get wind of any partnership news – in which case we might rotate in later. - For **EPM**: this would be a defensive move, and right now we choose to stay offensively positioned. If our portfolio had no stable elements, we might add this for ballast, but since the experiment is ending soon, the priority is asymmetric upside. We're aware EPM's steady dividend and low beta could cushion volatility, but it likely won't move the needle on overall returns by Dec 27. Thus, we opt to keep it on watch (for any major oil price moves) but not initiate now.

In summary, the active changes are: **Sell MBOT (exit completely)** and **Buy PRSO (new position)**. We will maintain MIST and AYTU as is, with stops unchanged. This repositions the portfolio with three holdings: one biotech FDA play (MIST), one pharma launch play (AYTU), and one special-situation tech play (PRSO). We believe this mix still leans into high-alpha opportunities but spreads risk across independent drivers.

Exact Orders

Below we list the **exact trade orders** we plan to execute at the start of Week 19. Each order includes all required details: action, ticker, number of shares (full shares only), order type (limit or market), limit price and conditions, time-in-force, intended execution date (next trading day, 2025-11-03), and stop-loss placements for new buys.

Order 1: Sell MBOT (Exit Position)
- **Action:** Sell
- **Ticker:** MBOT (Microbot Medical Inc.)
- **Shares: 7 shares** (entire remaining position; full shares only)
- **Order Type:** *Limit* (DAY) – we prefer a limit to ensure we don't sell at a sudden unreasonable low.
- **Limit Price:** $2.20 per share.
- **Time in Force:** DAY (order valid for Monday 2025-11-03 trading session only).
- **Intended Execution Date:** 2025-11-03 (Monday).
- **Stop-Loss:** *Not applicable* (this is a sell order closing the position; our prior stop at $2.30 was already breached, hence this sell).
- **Special Instructions:** We set the limit slightly below Friday's close ($2.23) to increase likelihood of execution, given MBOT's volatility. If the stock opens strong above $2.20, we will adjust/sell at market if needed, but $2.20 should hit if current weakness persists. We do **not** want to use a market order here due to potential illiquidity early in the session; a limit protects us from any sudden drop at open.
- **Rationale:** This order implements our decision to **exit MBOT** after its stop-loss was triggered. The goal is to preserve capital by getting out around the current market price. A $2.20 limit is just below recent trading, which is a reasonable expectation for Monday's trading range. We want out expeditiously, so a Day order is used. (If it somehow doesn't execute on Monday because MBOT spikes above our limit, we might re-evaluate – but given we **want to exit**, we may then chase with a higher limit or market order in that scenario. For now, $2.20 limit DAY is the plan.)

Order 2: Buy PRSO (New Position Initiation)
- **Action:** Buy
- **Ticker:** PRSO (Peraso Inc.)
- **Shares: 20 shares**
- **Order Type:** *Limit* (GTC) – we will place a limit buy to control entry price. GTC so that if it doesn't fill immediately (e.g., stock ticks up), it remains active for subsequent days.
- **Limit Price:** $1.45 per share.
- **Time in Force:** GTC (Good-Til-Cancelled, starting 2025-11-03)
- **Intended Execution Date:** 2025-11-03 (order placed on this date; if not fully filled, remains in market until filled or canceled).
- **Stop-Loss (for new buy): $1.10** per share. This stop order will be set after entry to limit downside (~-24%). It's placed just below a recent support area (around $1.15) and below round-number $1.20, to avoid getting clipped by normal volatility. If PRSO falls to $1.10, it likely means no deal is happening or some negative

development, so we'll cut our loss.
- **Special Instructions:** We chose $1.45 limit because the last close was $1.43 [20]. This gives us a small allowance in case it upticks at open. We do not want to chase much above that; if PRSO opens significantly higher (e.g., news leaked of a higher bid), we might reassess the risk (but likely that would actually be a positive!). The GTC ensures if it doesn't fill Monday (say it trades $1.46 all day), the order remains to catch any dip. Once filled, we will immediately set the stop-loss at $1.10 GTC.
- **Rationale:** This order establishes our **new position in PRSO**, aiming to capitalize on the M&A catalyst. 20 shares at $1.45 will cost about $29, which is within our available cash from the MBOT sale and cash reserve. We use a limit to avoid paying above our risk/reward comfort zone. GTC is used to avoid needing to re-enter the order if not filled in one session. The stop-loss at $1.10 defines our maximum loss on this trade (~$0.35 per share, ~24%), aligning with our risk tolerance. This buy brings a new non-biotech catalyst into our portfolio with manageable downside.

(No other orders are being placed this week.) We will maintain existing positions MIST and AYTU with their current stops, but those don't require new orders since the stops are already in place from prior weeks (we will adjust those orders only if we choose to tighten/loosen stops, which we are not this week). So, no new order for MIST/AYTU – just continue to hold.

Summary of Orders: To recap in a concise form: - **Sell 7 MBOT @ $2.20 limit DAY (on 11/03/2025).** – Exit MBOT position. - **Buy 20 PRSO @ $1.45 limit GTC (start 11/03/2025).** – Enter PRSO position, with **stop-loss $1.10 GTC** once filled.

These orders abide by all constraints (full shares, within cash budget, micro-cap universe, etc.) and set us up for the strategy we outlined.

Risk And Liquidity Checks

After the above trades, we perform a thorough check on portfolio concentration, liquidity impact, and overall risk profile:

Portfolio Concentration (Post-Trades): We will have 3 active positions – MIST, AYTU, and PRSO – plus a small cash buffer. Let's estimate approximate weights: - **MIST:** Current value ~$1.92 * (shares we hold, say ~20 shares) ≈ $38.4. This could be roughly ~41% of our total portfolio value (which will be around $93 after trades). - **AYTU:** ~$2.27 * (we hold ~10 shares) ≈ $22.7. That's about ~24% of portfolio. - **PRSO:** $1.45 * 20 shares = $29.0. That's ~31% of portfolio. - **Cash:** Leftover ~$5 (approx 5% of portfolio). These are rough, but indicate **no single position exceeds ~45%**. MIST remains the largest holding (~40-45%), which aligns with our conviction and its near-term catalyst. PRSO and AYTU are each roughly 25-30%. This is a fairly balanced distribution given we intentionally overweight MIST slightly for its asymmetric potential. Importantly, our positions are in three different industries (biotech, pharma, semiconductor), which diversifies idiosyncratic risk (e.g., an FDA sector-wide issue wouldn't directly hit PRSO, and a tech market swoon wouldn't directly hit MIST's odds of approval). We are aware that MIST and AYTU both depend on healthcare outcomes, but one is regulatory and one is commercial – independent triggers. **No concentration limits are breached**; all positions are within tolerable ranges for an aggressive portfolio.

Cash After Trades: We anticipate having a small cash reserve remaining. Calculating precisely: - Starting cash: $18.50. - Cash from selling MBOT: 7 shares * $2.20 = $15.40 (approx). Add to cash -> ~$33.90 total. -

Cash used to buy PRSO: 20 shares * $1.45 = $29.00. - Remaining cash = $33.90 – $29.00 = **$4.90** (approximately). We’ll round and say roughly **$5 cash** left. This residual cash (~5% of portfolio) serves as a cushion for any unforeseen expenses (commissions, slippage) and gives us a little flexibility (we could use it to top-up a position opportunistically or to pay for trade fees, etc.). We are under the hard budget (we did not use any external funds). This cash also slightly reduces full investment risk – it’s small, but in a drawdown it limits total exposure by a bit.

Stop-Loss Coverage and Risks: - With MIST ($1.70 stop) and AYTU ($1.80 stop) unchanged, our downside on those is limited. If worst-case both hit stops, the losses from current would be ~12% on MIST and ~21% on AYTU – painful but contained. - PRSO’s new stop at $1.10 caps its downside at ~-24% from entry. These are within acceptable loss percentages for high-risk positions. We should note: stops are not guaranteed to execute right at the level if a stock gaps down (especially relevant for something like PRSO on an abrupt no-deal news – it could open below $1.10 and our sell would execute at the best available price, maybe lower). However, given PRSO’s situation, a gap down might not be extreme (if talks fail, perhaps back to $0.7-0.8). So worst-case loss on PRSO might be a bit more than 24%, but that’s ~<$10 in absolute terms. Overall, each position’s risk is independent: MIST failure doesn’t affect PRSO, etc. So we don’t expect a single event to stop out the entire portfolio simultaneously (except an overall market crash, which is unlikely to specifically hit these microcaps more than they’ve already been hit – they trade on idiosyncratic news mostly).

Liquidity and Order Size Check: - **MBOT Sell:** MBOT’s average volume was ~2 million shares/day recently [26]. We are selling 7 shares – **this is negligible (<0.0004% of daily volume)**. We can easily exit without moving the price. Even considering lower liquidity at the open, 7 shares is trivial. - **PRSO Buy:** PRSO’s volume has been a few hundred thousand shares/day (e.g., 383k on Nov 1 [20]). Our purchase of 20 shares is about **0.005% of daily volume** – again extremely small. We won’t have any market impact. We chose limit orders also to avoid any wide bid/ask issues (though PRSO’s spread is usually only a few cents). - **General:** None of our orders are larger than the typical trade lot for these stocks. We aren’t concentrated enough to be considered insiders or affiliates obviously. So no regulatory or liquidity issues. - **Slippage:** By using limit orders, we largely control slippage. MBOT’s limit $2.20 is below last close, acknowledging we’re okay selling a bit lower to get out – this could incur a cent or two of slippage versus an ideal mid-point price, but it’s minimal in dollar terms. PRSO’s buy at $1.45 could miss if the stock is strong; but then we might adjust – as of now it’s likely to fill since $1.43 was last price. - **Bid/Ask spreads:** MBOT typically has a spread of a few cents; PRSO also a few cents. Not an issue for our small orders.

Risk of New Catalyst Play (PRSO): It’s worth explicitly noting risk: PRSO’s outcome is binary on deal vs no deal. By position sizing it ~30% of portfolio and having a stop, we manage this. If no deal and it triggers $1.10, we’d lose ~ $0.35*20 = $7. That’s about 7-8% of portfolio – not devastating. If a deal happens at e.g. $1.70, we gain $0.25*20 = $5, ~5% portfolio gain. If a bidding war or higher outcome ($2+), even better. So risk vs reward is reasonable.

Overall Portfolio Volatility: Likely to remain high. We now have two binary biopharma bets and one binary M&A bet. Expect our daily P/L to swing accordingly. We accept this because the potential upside swings (MIST approval + PRSO deal + AYTU strong launch) could dramatically outpace the broader market, which is our objective. We’ve mitigated catastrophic downside by stops – worst-case if all stops hit (MIST FDA fail, AYTU bad news, PRSO no deal), we would drop to roughly the cash-out values: MIST $1.70, AYTU $1.80, PRSO ~$1.10 – which would leave the portfolio around maybe $60-$65 value plus cash. That would be a ~30% drop from here – unpleasant, but *not* a zero, and highly unlikely all three fail concurrently in such short span. On the flip side, the upside of even one success is big (e.g., MIST approval might double or triple that position). So the **risk/reward trade-off is consciously aggressive** but with guard rails.

Compliance Checks: All chosen stocks are U.S. listed (NASDAQ/NYSE American). Market caps: MIST ~$160M [7], AYTU ~$22M [9], PRSO ~$11M (with our buy at ~$1.45 for ~7.8M shares outstanding [27]). All under $300M, so compliant. No margin or complex instruments used – all straightforward equity trades. No position exceeds portfolio cash (no leverage). We have also considered **liquidity risk around stops** – e.g., if MIST's FDA decision comes out after hours on Dec 13 and it's bad, the stop might execute next day at a much lower price (gap risk beyond stop). This is a known limitation; we accept that residual risk because it's inherent in binary biotech. But we at least have the stop to attempt to get us out.

In conclusion, after these trades, the portfolio will consist of 3 names each with independent catalysts, none excessively large, with **total exposure ~$88 (invested) + $5 cash = $93**. We've **balanced the high upside potential with prudent risk controls** (diversification and stops). Liquidity is more than sufficient for our trade sizes, so execution risk is minimal. We will remain vigilant, especially as catalyst dates approach, to adjust stops or take profits as needed to further manage risk.

Monitoring Plan

In the coming week(s), we will closely monitor each position and external factors, with a readiness to adjust if needed. Our monitoring and contingency plans are as follows:

Milestone (MIST): The critical date is **Dec 13, 2025 (PDUFA)**. Leading up to that: - **Weekly checkpoints:** We will watch for any FDA communications or analyst notes regarding MIST. Particularly, sometimes FDA releases briefing documents or there are rumors if an Advisory Committee was convened (though none is planned for MIST as far as we know). We'll also keep an eye on competitor news (if any alternative PSVT therapies get news, though MIST is unique here). - **Price action:** As we approach late November/early December, if MIST shares start climbing significantly (a "run-up"), we might consider managing the position (e.g., take a bit of profit or tighten the stop to lock in gains while still holding most for the decision). Conversely, if the stock drifts down for no reason and approaches our stop, we'll be cautious – it could indicate negative rumors. We would likely stick to the stop discipline regardless. - **Stop-loss management:** Currently $1.70. If by early December MIST runs up (say to $2.5-$3 pre-decision on optimism), we will likely **raise our stop** to protect some profit (perhaps to around our entry or higher, to ensure a winning trade even if approval ends up negative). If MIST stagnates, we leave the stop as-is. If any **bad news leaks early** (e.g., an unexpected FDA delay or additional requests), we might sell immediately rather than wait for stop. - **Post-catalyst:** If FDA approves etripamil on Dec 13, we will have to decide quickly whether to sell on the pop or hold for further upside. Given the experiment ends Dec 27, we'd likely take profits shortly after an approval spike (we can't get too greedy with only 2 weeks left). If FDA rejects, our stop will trigger and we'll exit to prevent further bleed.

Aytu (AYTU): This is more of a slow-burn catalyst (commercial rollout): - **Launch news:** We expect a press release once EXXUA is actually available for prescribing. We're watching company news daily. Additionally, any early indicators (script volume, physician feedback, maybe coverage by insurance or inclusion in guidelines) will be monitored via news or perhaps AYTU management commentary. - **Conferences/Calls:** AYTU may present at healthcare conferences or do a year-end update. We'll listen for any commentary on how the launch is going. Since the drug is set for Q4 launch, initial sales numbers might not be public until the next earnings call (which might be after our timeframe). However, even *anecdotal positive news* could move the stock. - **Price/Stop management:** The $1.80 stop is well below current price. If AYTU remains stable or trends up slowly, we'll keep the stop. If it surges (say on a positive launch development) into the $3+ range, we might take partial profits or at least raise the stop to secure gains. If it unexpectedly plunges (no obvious news), that could signal a hidden problem (e.g., maybe launch delayed or broader market sell-off). We'd likely let the stop $1.80 do its job in that case. - **Dilution risk:** We believe AYTU doesn't need near-term cash (they did financing in June at $1.50). But we'll monitor SEC filings just in case they file any new shelf offerings or ATM usage. Any hint of dilution could pressure the stock, and we might re-evaluate if we see that. - **Timeline note:** By Dec 27, we might not have concrete sales data, so this position may rely on sentiment. We'll gauge sentiment through any analyst coverage or media coverage of EXXUA's launch (e.g., if doctors appear enthusiastic, etc.). If nothing materializes by mid-December and the stock is flat, we'll have to decide at experiment end whether to keep or exit at whatever price (for experiment purposes likely we'd close it on Dec 27, capturing whatever value then).

Peraso (PRSO): This one requires **daily monitoring** given it's an event-driven situation: - **News monitoring:** We will keep a very close eye on press releases from Peraso and Mobix Labs, as well as any SEC filings (e.g., if a formal merger agreement 8-K is filed, or if Mobix increases its offer or goes hostile). Because this is a corporate action situation, news could break anytime (pre-market, trading hours, or post-market). - **Stock price movement:** PRSO can be very reactive to rumors. For instance, if suddenly the stock spikes on high volume to $1.70-$2, that likely indicates a deal or a rumor of one – we would then look for confirmation to potentially sell into strength (especially if it exceeds our expectations). Conversely, if we see PRSO drifting below $1.20 on volume, that could signal deal trouble (or just impatience). We have a stop at $1.10, but we'll also qualitatively assess: if no news but price weak, do we stick it out or cut early? Probably stick to stop, unless we hear something concrete like "talks terminated" – in which case we might not wait for $1.10, we might sell immediately around market prices to avoid further slide. - **Timeframe:** Mobix's initial unsolicited bid was in June; it's now early Nov and they're under NDA. They likely will want to wrap this up. We suspect we'll have resolution within a few weeks (either a announced merger or Mobix walking away). If by mid-December nothing is announced, we'll have to decide to hold or sell. Possibly, absence of news might mean negotiations extended or seeking other bidders. We'd evaluate based on stock price then. Given our experiment ends Dec 27, if no deal by say Dec 20, we might cut our losses/profits on PRSO to avoid being stuck in limbo. But we'll see – ideally, we get news soon. - **Stop-loss:** We will have a GTC stop at $1.10. We will monitor intraday—if PRSO suddenly tanks on huge volume, it likely means bad news and our stop will trigger. We'll check execution if that happens. If a partial fill or something odd occurs, we'll manually ensure we're out. - **Upside strategy:** If a deal is announced, typically the stock will trade close to the deal price (if it's a cash deal, it will gravitate a few cents below deal price until closing). In that event, with only weeks left, we'll likely take the money and move on to avoid closure risk. For example, if a $1.50 cash deal is announced, PRSO might trade ~$1.45-$1.48; we'd likely sell our shares around there rather than wait months for official closing. If a higher competing bid emerges quickly, we'll reassess holding a bit longer but likely still exit before experiment end.

Overall Monitoring: - We will set up **price alerts** for all three stocks on our trading platform (e.g., alert if MIST falls < $1.75 or rises > $2.50; AYTU falls < $1.90 or rises > $2.70; PRSO falls < $1.15 or rises > $1.60) to ensure we don't miss significant moves intraday. - We'll review news at least **daily** (morning and evening) for each holding. Microcaps can have sporadic news flow, so vigilance is key. - The **general market environment** will be watched too. If there's extreme market volatility (e.g., small caps selling off), we might adjust our approach (perhaps lighten something or delay a buy if spreads blow out). Though our names are more catalyst-driven, a severe risk-off in markets can still drag everything down short-term. - **Next Weekly**

Window: By next Sunday (Week 20), we'll have a fresh chance to adjust. Our plan is somewhat set through mid-December catalysts, but we remain flexible. For instance, by next week, if PRSO hasn't moved, we'll evaluate if holding is still justified or if any new info arises. If any of our stops hit during the week, we will log that and be prepared to reallocate or hold cash as appropriate next weekend. - **Contingency Plans:** - If MIST or AYTU triggers stops unexpectedly early (far ahead of their catalysts), we'll analyze why. If it's a broad market issue and we still believe in them, we might re-enter or lower the stop. But if it's company-specific bad news, we would stay out once stopped. - We have identified a few backup ideas (e.g., CMPS or others like PESI) that we can rotate into if needed. So if we exit something and free cash, we can quickly deploy into those if their story is intact. - Also, if by late November our portfolio has appreciated and we want to **lock in some gains** to ensure a respectable finish, we might take partial profits or raise stops as a defensive measure heading into final weeks. We'll evaluate that with an eye on the experiment end-date: we don't want to snatch defeat from jaws of victory by being too greedy at the end.

In summary, **we will monitor news feeds and price action daily** for all holdings, adjust stops if necessary, and remain nimble. Each position has clear trigger points (MIST – FDA date; AYTU – launch progress; PRSO – deal news). We'll be particularly alert around those events to execute our plan (taking profit or cutting loss). Our risk management via stops is in place, but we supplement it with active oversight – stops are last-resort; we may act even before a stop if our judgment and research indicate to. Communication frequency: given the short timeframe left, we will likely review the portfolio *at least daily*, with deeper analysis each weekend and any time a major event occurs.

Thesis Review Summary

To conclude, let's summarize the investment thesis for each current holding (and our new addition) and why we believe our portfolio is positioned well for the final stretch of this experiment:

Milestone Pharmaceuticals (MIST) – Thesis: MIST is our high-conviction biotech bet on an upcoming FDA approval. The company's **etripamil nasal spray (Brand: "Cardamyst")** could become the **first self-administered therapy for paroxysmal supraventricular tachycardia (PSVT)** [2], a condition where currently patients often rush to the ER to get intravenous medication. This is a *game-changer* if approved – it empowers patients to treat episodes at home, addressing a clear unmet need. The FDA's prior concerns were *not* about the drug's efficacy or safety (those were demonstrated in trials), but about chemical manufacturing controls (nitrosamine impurities and a facility inspection) [2] [28]. MIST resubmitted with fixes, and the FDA set a **Dec 13, 2025 PDUFA date** [1]. Our thesis is that MIST has a strong chance of approval given positive clinical data and resolved CMC issues. If that happens, we expect a significant stock re-rating (potentially 100%+ upside, as indicated by at least one analyst's $4 price target [19]). We acknowledge it's a binary, but we've accepted that risk. The reward, if realized, would likely make MIST the star of our portfolio. We placed a stop at $1.70 to cap downside (roughly a 10-15% loss limit) in case of a surprise negative outcome (e.g., another delay or rejection). So far, MIST's stock has been stable – a sign that the market is waiting. We see that as neither bullish nor bearish, just equilibrium. **This week's update:** No new news on MIST, which we interpret as everything proceeding normally with the review. The stock holding in the high $1.80s is fine. We remain **bullish** and will carry MIST into its catalyst. *Our plan:* hold through the FDA decision, as the risk/reward is still strongly in our favor. We're effectively in "calm before the storm" mode – and we're ready for potentially big news by the next few weeks. **In summary,** MIST encapsulates our willingness to take a calculated high-risk shot for a high payoff, with controls in place (stop-loss) to prevent devastation.

Aytu BioPharma (AYTU) – Thesis: AYTU is a small-cap specialty pharma that we view as a **deep value with a catalyst**. It's launching **EXXUA™ (gepirone ER)**, an FDA-approved novel antidepressant. Why is EXXUA special? It's the **first antidepressant in decades with a new mechanism** (5-HT1A receptor partial agonist) and notably **lacks the sexual side effects** that come with SSRIs and SNRIs [16] [29]. Sexual dysfunction from antidepressants is a huge issue leading to poor adherence. EXXUA could carve out a meaningful niche in the ~$22 billion US depression market [17], even if only as a second-line or for patients who can't tolerate SSRIs. AYTU's market cap is only ~$22M [18], which means the market is essentially assigning almost no credit to EXXUA's potential. We think this is an overreaction to AYTU's past (they've had a history of small products and dilution). Now, however, they have fresh funding (they raised ~$16M at $1.50 in June, which major healthcare funds participated in [30]), and they have an existing sales force (from their ADHD products) to leverage for EXXUA's launch. Our thesis is that as EXXUA launches (target: Q4 2025 [31]), investors will start to see that AYTU could generate significant revenue in 2026 and beyond, making the current valuation look absurdly low. Even a path to, say, $10M-$20M in annual sales (a tiny fraction of the market) could justify multiples of the current price. **This week's update:** AYTU stock stayed around $2.30, which is fine. The company announced a patent term extension to 2030 for EXXUA [32] – good for the long-term value (it ensures they have exclusivity beyond the standard 5-year NCE). Also, management reiterated the launch is on track and they're actively engaging investors. No negatives emerged. We remain confident that **the launch will proceed in the coming weeks**, and we'll be watching for that announcement. *Risks:* Launch execution – since this is a new kind of therapy (although it's a pill, so not a tough sell like psychedelics or something). Also, AYTU is small and might need more capital in late 2024 if revenues ramp slowly (but near-term they should be fine). We set a stop at $1.80 to protect from any downside surprise (e.g., if launch were inexplicably delayed or initial uptake is poor). **In summary,** AYTU offers a more gradual, fundamentally driven upside that complements our binary picks. We like that it has real revenue from other products and isn't purely story – that gives it some floor value. We expect by the end of the experiment, as EXXUA hits the market, AYTU's stock will be higher, potentially significantly if any early traction is seen. We'll remain patient and let this play out, intervening only if something materially threatens our thesis (none so far).

Peraso (PRSO) – Thesis: Peraso is our new addition, representing a special situation: **an imminent takeover possibility**. PRSO is a tiny tech company (semiconductor IP for wireless) that, on its own, was struggling – but it has become a target of interest by a private company, Mobix Labs. Our thesis is that **there's a high likelihood that Peraso will be acquired or merge at a premium in the near future.** Mobix's all-cash offer of $1.30/share in June and their persistence (they went public with it and then got Peraso to sign an NDA in October) suggests serious intent [11]. We suspect that either Mobix will raise its offer or Peraso, after shopping around, might agree to a deal. The stock trading above $1.30 (around $1.40s) indicates the market also expects a higher final price or outcome. From a risk perspective, if no deal happens, PRSO likely falls, but we've mitigated that with a stop. **Why do we like this?** It's a pure catalyst that is *time-bound* and not dependent on broader market or economic conditions. It's also uncorrelated to our other two holdings. Essentially, PRSO could give us a win (say +20%) regardless of what happens with MIST or AYTU, which is attractive for balancing risk. **This week's update:** We initiated the position. The key "update" here is that as of Oct 30, we know they are in confidential talks [11]. That itself is an update from a month ago when it was just an unsolicited offer. So momentum is positive – they are talking instead of ignoring the bid. *Risks:* The obvious risk is talks fall apart. Peraso might have been hoping for a higher bid or another bidder (none public so far). If Mobix walks away, the stock could drop hard. We're guarding against that with a tight stop. The other risk is that even if a deal is agreed, it might not close by Dec 27 (most likely it wouldn't; closing takes months). But that's okay – we don't need it to close, we just need the announcement so the stock reprices upward and then we can sell into that strength. **Liquidity risk:**

minimal for our small stake, but in general, microcap M&A can see volatility up until resolution. We'll monitor closely. **In summary,** our PRSO thesis is that we have a high probability of a controlled ~10-30% gain on a deal announcement, versus a limited downside if it fails, making it a smart gamble with our otherwise unused cash. It adds a different kind of catalyst (corporate action rather than drug or sales outcome). We'll execute our plan by sticking to news flow and react accordingly.

Portfolio-Level Summary: Our portfolio now essentially has *three independent shots on goal:* 1. **Regulatory Approval (MIST)** – a yes/no event that could multiply that position. 2. **Commercial Success (AYTU)** – a gradual catalyst where each positive sign can lift the stock, representing a revaluation story. 3. **Acquisition (PRSO)** – a binary event likely to yield a one-time pop if it occurs.

Each carries significant upside potential: - MIST: could double or more on approval (PSVT market is large and unmet; plus contingent $75M financing upon approval will secure its financial future [33]). - AYTU: could realistically double if EXXUA launch feedback is good (given how undervalued it is and the huge market, any traction could rerate it). - PRSO: might gain 20-50% if a deal is announced (depending on final price). Simultaneously, we've put **risk controls** under each: stop-loss orders and careful position sizing so that if one blows up, the portfolio survives to benefit from others. We acknowledge that our strategy is aggressive – it has to be, to catch up from being behind the S&P. But it's a **calculated aggression** focusing on known catalysts within our timeframe.

Looking Ahead (Next Week and Final Weeks): We will continue to refine our theses as events unfold: - For MIST, as the decision draws nearer, our focus shifts to *when* to possibly take profit (maybe sell a portion before PDUFA if it runs, or all after event). - For AYTU, we'll look for tangible indicators of market acceptance for EXXUA – any such news will strengthen our thesis that AYTU is deeply undervalued. - For PRSO, each day without news slightly increases risk (time decay of a catalyst), but so far no red flags – if anything, the longer talks go, one might think they're ironing out details (which is positive). We'll refine our exit plan once any deal is known.

In summary, we're entering the final phase of this experiment with a **focused, catalyst-rich portfolio**. We have high conviction in each position's thesis: - **MIST:** Transformative FDA-approved therapy potential – **holding for binary win**, tightly controlling downside. - **AYTU:** Launch of a novel drug in a huge market – **holding for revaluation** as sales emerge, moderate downside due to underlying value. - **PRSO:** Likely takeover target – **holding for deal announcement**, with very limited downside (stop in place).

Each thesis is **independent**, which is ideal for diversification: success or failure of one should not directly impact the others. We have multiple shots for a strong finish. We will execute diligently according to our research, and we remain vigilant on risk management at every step.

With these adjustments and our continuous monitoring, we feel the portfolio is **optimized for risk-adjusted returns** given the circumstances – we've respected all rules and constraints, and we're prepared to adapt quickly as news hits. Now, we let our theses play out, with confidence in our research and a clear plan for whatever comes next.

Cash and Constraints Check: After trades, we expect ~$5 cash left (no new capital used, within budget). All positions conform to micro-cap < $300M rule (MIST ~$160M [7], AYTU ~$22M [9], PRSO ~$11M). We will trade only full shares and have placed limit orders to ensure execution control. All stop-loss orders are set as required. We are fully compliant with the experiment's rules, and ready to execute the plan as detailed.

[1] [28] Q4 2025 FDA Preview: 10 Decisions to Watch | HCPLive
https://www.hcplive.com/view/q4-2025-fda-preview-10-decisions-to-watch

[2] [7] [33] MIST - Milestone Pharmaceuticals Latest Stock News & Market Updates
https://www.stocktitan.net/news/MIST/

[3] [4] [32] Aytu BioPharma Secures 5-Year EXXUA Patent Extension to 2030 | AYTU Stock News
https://www.stocktitan.net/news/AYTU/aytu-bio-pharma-announces-patent-term-extension-for-exxua-p9v4jb47xvvv.html

[5] [6] Microbot Medical Announces LIBERTY Limited Release in Q4 2025 | MBOT Stock News
https://www.stocktitan.net/news/MBOT/microbot-medical-secures-u-s-based-logistics-partner-to-support-the-3mu8rca176j3.html

[8] [9] AYTU - Aytu Biopharma Inc Latest Stock News & Market Updates
https://www.stocktitan.net/news/AYTU/

[10] Mobix Labs Moves Decisively with All-Cash $1.30 Per Share Offer ...
https://www.fidelity.com/news/article/mergers-and-acquisitions/202510060700PRIMZONEFULLFEED9540423

[11] [8-K] Peraso Inc. Reports Material Event | PRSO SEC Filing - Form 8-K
https://www.stocktitan.net/sec-filings/PRSO/8-k-peraso-inc-reports-material-event-ea0ca1ee01f2.html

[12] COMPASS Pathways Plc (CMPS)' Psilocybin Therapy Hits Phase 3 ...
https://finance.yahoo.com/news/compass-pathways-plc-cmps-psilocybin-074722156.html

[13] [14] [24] [25] 6 High-Potential Micro-Cap Stocks for 2025 | Valuesense
https://blog.valuesense.io/micro-cap-stocks-2025/

[15] AZTR - Azitra Inc Latest Stock News & Market Updates
https://www.stocktitan.net/news/AZTR/

[16] [17] [18] [29] [30] [31] Aytu BioPharma Raises $16.6M for Revolutionary Depression Drug Launch | AYTU Stock News
https://www.stocktitan.net/news/AYTU/aytu-bio-pharma-announces-closing-of-upsized-at-the-market-public-5l07ps6yaqd8.html

[19] Wells Fargo Initiates Coverage on MIST with Overweight Rating |
https://www.gurufocus.com/news/3104263/wells-fargo-initiates-coverage-on-mist-with-overweight-rating-mist-stock-news

[20] Peraso Inc. Common Stock (PRSO) Historical Quotes - Nasdaq
https://www.nasdaq.com/market-activity/stocks/prso/historical

[21] CMPS - Compass Pathways Plc Latest Stock News & Market Updates
https://www.stocktitan.net/news/CMPS/

[22] COMP360 Psilocybin for Treatment-Resistant Depression: Positive ...
https://www.psychiatrictimes.com/view/comp360-psilocybin-for-treatment-resistant-depression-positive-phase-3-efficacy-data

[23] COMPASS Pathways (CMPS) Stock Price & Overview
https://stockanalysis.com/stocks/cmps/

[26] Microbot Medical Inc. Common Stock (MBOT) Historical Data - Nasdaq
https://www.nasdaq.com/market-activity/stocks/mbot/historical

[27] Peraso (PRSO) Stock Price & Overview
https://stockanalysis.com/stocks/prso/